Both in Pharmaceuticals
Aktis Oncology vs Alto Neuroscience
Over the past year AKTS returned −33.3% and ANRO returned +38.7%; their daily moves had a correlation of 0.25.
AKTS −33.3% ANRO +38.7%Growth of $1, one year, split-adjusted
| Metric | AKTS | ANRO |
|---|---|---|
| Price | $14.94 | $22.70 |
| Market cap | $831.0M | $890.8M |
| Today | +2.40% | +2.30% |
| 1 month | −19.3% | −5.5% |
| 6 months | −23.1% | −10.8% |
| Year to date | — | +27.5% |
| 1 year | — | +60.0% |
| Revenue growth (YoY) | — | — |
| Gross margin | 100.0% | — |
| Net margin | −713.5% | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $517.3M | $225.1M |
| Dividend yield | — | — |
| Volatility (60d) | 55.5% | 56.3% |
| Short % of float | 18.3% | 20.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).